Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2126)

INSIDE INFORMATION
INCLUSION OF CARTEYVA® (RELMACABTAGENE AUTOLEUCEL INJECTION) IN THE NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by JW (Cayman) Therapeutics Co. Ltd (the "**Company**" or "**JW Therapeutics**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is pleased to announce that Carteyva® (relmacabtagene autoleucel injection), the Company's core product, has been officially included in the 2026 edition of the National Reimbursement Drug List (NRDL). With effect from January 1, 2027, patients using Carteyva® within the national medical insurance reimbursement scope may be reimbursed under basic medical insurance in accordance with applicable regulations. The reimbursement scope covers three approved indications of Carteyva®, including large B-cell lymphoma (LBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). The price for Carteyva® included in the NRDL is RMB288,600.

As the only chimeric antigen receptor T-cell (CAR-T) therapy product included in the NRDL in this round, Carteyva® will further lower the payment threshold for eligible patients to receive CAR-T treatment, promoting the accessibility of this cutting-edge innovative therapy to more patients. With further improvement in payment coverage, CAR-T treatment is expected to be incorporated into clinical treatment decisions more broadly, facilitating the timely identification, referral and assessment of patients who may benefit. Clinicians can comprehensively assess treatment options and timing of intervention based on patients' disease progression, prior treatment history and individual needs, so as to formulate more appropriate treatment plans for eligible patients.

Since its launch, Carteyva® has continued to accumulate long-term follow-up data from registrational studies and real-world practice evidence. As of October 31, 2026, the longest follow-up in registrational clinical studies of Carteyva® has reached 8 years; cumulatively, more than 1,200 patients have received Carteyva® treatment, and the product covers more than 200 certified treatment centres nationwide. Relevant clinical applications have also been recommended by authoritative domestic medical guidelines. Meanwhile, the post-marketing real-world study of Carteyva® (CTR20221920) has collected data from 200 patients, continuously providing a practical basis for evaluating efficacy, safety and long-term benefits in different clinical settings. From long-term follow-up in registrational clinical studies to continued application in the real world, the continuously accumulating clinical evidence and treatment practice of Carteyva® provide important support for its standardised application across different indications. With further improvement in access to medical insurance coverage, these well-established clinical benefits, supported by ongoing evidence and accumulated clinical experience, are expected to translate into actual treatment benefits for more eligible patients.

Since its commercialisation, Carteyva® has achieved a one-time manufacturing success rate of 99% and a product delivery rate of 100%. This commercial manufacturing performance reflects the Company's mature experience accumulated in the manufacturing and delivery of personalised cell therapy products, and also provides an important foundation for accommodating the potential growth in patient treatment demand following the implementation of medical insurance coverage.

JW Therapeutics has always placed product quality and patient safety first. With the inclusion of Carteyva® in the NRDL, the Company will continue to strictly comply with Good Manufacturing Practice for Drugs, implement the approved manufacturing processes, quality standards and product release requirements, and continue to ensure product quality and safety.

At the same time, the Company will continue to advance the optimisation of manufacturing processes, the enhancement of its quality management system and the improvement of operational efficiency, so as to further strengthen its large-scale manufacturing and stable delivery capabilities while ensuring the consistency and reliability of product quality, thereby providing strong assurance for more patients to receive high-quality CAR-T therapy as intended.

In recent years, JW Therapeutics has made continuous progress in the field of proprietary core technologies. The suspension lentiviral vector (sLVV) process platform independently developed by the Company has established comprehensive technical capabilities encompassing process development, large-scale manufacturing and quality control, providing essential technical support for the production of CAR-T products and subsequent innovation pipelines. Leveraging its mature commercialisation experience and its independent innovation platform, JW Therapeutics is continuing to advance differentiated innovation pipelines, including JWCAR239 with potential first-in-class value — an autologous CAR-T candidate designed with dual-targeting CD19/CD20 and dual armoured elements, as well as an independently developed in vivo CAR-T technology platform.

Mr. Feng Tian, Chairman of the Board and executive Director of JW Therapeutics, said: "Cell immunotherapy is a focal area of global biopharmaceutical innovation and competition. CAR-T has brought hope of a cure to patients with hematologic malignancies, yet the high cost of treatment has deterred many families.

Today, with the successful inclusion of the relevant indications of relmacabtagene autoleucel injection in the NRDL, more patients are provided with the opportunity to access internationally advanced cell therapy at an affordable price. The shift from 'availability of medicines' to 'affordability of medicines' represents a historic leap in bringing innovative drugs to the benefit of patients.

This breakthrough would not have been possible without the strong support and guidance of national medical insurance policies, and it also embodies JW Therapeutics' years of independent technological innovation and industry optimisation. In particular, the recent technological breakthroughs in key manufacturing areas such as lentiviral vectors have given us the confidence of 'Intelligent Manufacturing in China', enabling us to achieve cost reduction at scale while upholding product quality, ultimately making innovative treatment more accessible and benefiting patients in China.

Technological innovation reduces costs, medical insurance support expands accessibility, and reasonable returns feed back into innovation. Such a virtuous cycle delivers benefits to patients while driving the development of the industry.

The fundamental value of pharmaceutical innovation lies in bringing innovations out of the laboratory and the production floor, into clinical practice, and ultimately into the lives of more patients."

About Relmacabtagene Autoleucel Injection

Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, relmacabtagene autoleucel injection has been approved by the National Medical Products Administration of the PRC (NMPA) for three indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after second-line or above systemic therapy; the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), and the treatment of adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) after second-line and higher systemic therapy including Bruton tyrosine kinase inhibitor (BTKi) treatment, making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, Carteyva® is the only CAR-T cell immunotherapy product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.

About JW Therapeutics

JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercialising cell immunotherapy products, and is committed to becoming a leader in cell immunotherapy with innovation at its core. Since its founding in 2016, JW Therapeutics has successfully built an internationally leading integrated platform for product development in cell immunotherapy, as well as a cell immunotherapy product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardised development of China's cell immunotherapy industry. For more information, please visit **www.jwtherapeutics.com**.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market relma-cel or Carteyva® successfully. Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Feng Tian
Chairman and executive Director

Shanghai, PRC, November 15, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Feng Tian as Chairman and executive Director, Dr. Yiping James Li, and Ms. Xing Gao as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu and Mr. Peng Kuan Chan as independent non-executive Directors.

* *For identification purpose only*